Starton Holdings, Inc.

S-1/A amended

S-1/A amended

Starton Holdings, Inc. is conducting an initial public offering (IPO) of 6,666,667 shares of common stock, with an estimated price range of $5.00 to $7.00 per share. The company, a clinical-stage biotechnology firm, focuses on developing continuous delivery systems for cancer therapies using its proprietary platform. Its lead program, STAR-LLD, involves low-dose lenalidomide formulations for hematologic malignancies, while another candidate, STAR-OLZ, targets chemotherapy-induced nausea but is currently on hold. The IPO aims to fund clinical trials and expand its pipeline, with shares expected to list on Nasdaq under the symbol 'STA'.

S-1/A amended

Starton Holdings, Inc. is conducting an IPO for 6,666,667 shares of common stock at an estimated price range of $5.00 to $7.00 per share. The company, a clinical-stage biotechnology firm, focuses on developing cancer therapies using proprietary delivery technologies. The S-1/A amendment reflects updates to the offering timeline, including the expected share delivery date in 2026 and structural changes such as a reorganization section. The filing emphasizes risks related to clinical trial outcomes, regulatory approvals, and reliance on key programs like STAR-LLD and STAR-OLZ.

S-1 filed

Starton Holdings, Inc. is a clinical-stage biotechnology company focused on developing cancer therapies using proprietary delivery technologies. The company is conducting an initial public offering (IPO) of 6,666,667 shares of common stock, with an estimated price range of $5.00 to $7.00 per share. The offering aims to fund continued development of its lead program, STAR-LLD, a continuous delivery system for lenalidomide, and other pipeline candidates. Starton is an emerging growth company and smaller reporting company, which affects its regulatory reporting requirements.

DRS/A amended

The current filing represents an amendment (DRS/A) to Starton Holdings, Inc.'s draft registration statement for an initial public offering (IPO) of common stock. The filing highlights the company's status as an emerging growth company and smaller reporting company, with plans to list on NASDAQ. Key elements include the proposed IPO price range, underwriting details, and a corporate reorganization (Domestication Transactions) to transition from a Canadian holding company to a Delaware entity, enabling tax deferral for Canadian shareholders. The previous DRS filing from December 2024 contained similar details but lacked the amendment-specific updates and finalized dates.

DRS filed

Starton Holdings, Inc. is preparing for its initial public offering (IPO) of [•] shares of common stock, with an estimated price range of $[•] to $[•]. The company is an emerging growth company and smaller reporting company, and has filed a confidential draft registration statement (DRS) with the SEC. The offering is contingent on the stock being listed on Nasdaq. The filing outlines a corporate reorganization (Domestication Transactions) to transition from a Canadian holding company to a Delaware-based entity, enabling tax deferral for Canadian shareholders. The prospectus highlights risks associated with the IPO, including market volatility, reliance on key personnel, and regulatory uncertainties.